Skip to content
HowShorted

Bionano Genomics, Inc. short interest in 2024

In 2024, Bionano Genomics, Inc.'s disclosed short interest ran from 12.59% of shares outstanding on 12 Jan 2024 to 17.31% on 31 Dec 2024, a change of +4.72 percentage points. The year's high was 17.31% on 31 Dec 2024 and its low 4.28% on 30 Aug 2024, averaging 10.14% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.20 days on 14 Jun 2024. Full history: Bionano Genomics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Bionano Genomics, Inc. in 2024

2024 in figures

Start of year
12.59% (12 Jan 2024)
End of year
17.31% (31 Dec 2024)
Change
+4.72 pp
High
17.31% (31 Dec 2024)
Low
4.28% (30 Aug 2024)
Average
10.14%
Highest days to cover
6.20 (14 Jun 2024)
SEC filings marked
10

Every report in 2024

Bionano Genomics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202412.59%2.36results (8-K)
31 Jan 202414.42%3.24
15 Feb 202414.50%3.44
29 Feb 20249.56%4.06
15 Mar 202410.01%3.3210-K filed, results (8-K)
28 Mar 20249.64%4.65
15 Apr 20249.79%2.65
30 Apr 20249.42%4.82
15 May 20249.11%4.1710-Q filed, results (8-K)
31 May 20248.57%4.41
14 Jun 20249.60%6.20
28 Jun 202410.56%3.67
15 Jul 20248.80%1.76
31 Jul 20248.17%3.43
15 Aug 20244.91%1.6110-Q filed, results (8-K)
30 Aug 20244.28%2.48
13 Sep 20244.84%4.58
30 Sep 20247.06%4.12
15 Oct 20248.92%4.30results (8-K)
31 Oct 202411.43%3.02
15 Nov 202411.88%3.54results (8-K), 10-Q filed
29 Nov 202412.41%3.90
13 Dec 202415.53%5.59
31 Dec 202417.31%1.77

See also: Bionano Genomics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.